Search Results

You are looking at 61 - 70 of 232 items for :

Clear All
Full access

Mehren, MD Conditions: Angiosarcoma Institution: Fox Chase Cancer Center Pazopanib has shown encouraging activity in a previous phase II trial in certain sarcoma subtypes. In the EORTC phase II trial of pazopanib, the progression-free rate at 12

Full access

Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Principal Investigator: David Loeb, MD, PhD Condition: Sarcoma Institution: The Sidney Kimmel Comprehensive Cancer Center at Johns

Full access

Vinod Ravi, Eric M. Sanford, Wei-Lien Wang, Jeffrey S. Ross, Naveen Ramesh, Andrew Futreal, Shreyaskumar Patel, Phillip J. Stephens, Vincent A. Miller and Siraj M. Ali

sarcoma center, and underwent definitive hyperfractionated radiotherapy of 200 cGy per fraction times 30 fractions (total dose of 6,000 Gy), and the patient remained disease-free for 39 months. In September 2011 the patient experienced facial swelling of

Full access

Michael J. Monument and Kevin B. Jones

amplifications. Many of these mutations and amplifications are shared between both differentiated and dedifferentiated components, suggesting a common cellular origin. 35 , 36 Ewing Sarcoma Ewing sarcoma is a quintessential translocation

Full access

Neoadjuvant Treatment of Soft Tissue Sarcoma Principal Investigator: William Tap, MD Conditions: Sarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma Institution

Full access

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas

Full access

Introduces New Guidelines for Patients With a Form of Cancer Associated with HIV and AIDS NCCN has created a new resource for patients living with HIV who develop AIDS-related Kaposi sarcoma. This newly-released NCCN Clinical Practice Guidelines in

Full access

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman and Hema Sundar

the United States and 1440 people will die of the disease. 3 Primary bone cancers demonstrate wide clinical heterogeneity and are often curable with proper treatment. Osteosarcoma (35%), chondrosarcoma (30%), and Ewing sarcoma (16%) are the most

Full access

following regimens were added for chordoma: Imatinib with cisplatin or sirolimus Erlotinib + cetuximab Sunitinib Ewing's Sarcoma: Under “Primary therapy for metastatic disease at initial presentation,” included the

Full access

Hassaan Raza Jafri, Isna Batool Khan, Ahmad Abu-Hashyeh, Vivek Yadala, Hassaan Yasin, Todd Gress and Maria Tirona

adjusted for gender and age. Results: Statistically significant factors associated with lower survival rate at 6 months included age greater than 60 (p=0.052), cancers such as melanoma and sarcoma (p=0.042), smoking (p=0.028), ECOG greater than 2(p=0